Conflict of Interest Disclosures: Dr Kadowaki reported grants and personal fees from Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co Ltd, Novo Nordisk Pharma Ltd, Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co Ltd, Sumitomo Pharma Co Ltd, Kyowa Kirin, Daiichi Sankyo, and Takeda Pharma; personal fees from MSD Corporation, Abbott Japan Ltd, Teijin Pharma Ltd, Ono Pharmaceutical Co Ltd, FUJIFILM Toyama Chemical Co Ltd, Medtronic Japan, and AstraZeneca outside the submitted work. Dr Heftdal reported nonfinancial support from OPEN Health Communications during the conduct of the study and is an employee and shareholder of Novo Nordisk outside the submitted work. Dr Ko reported grants from Novo Nordisk during the conduct of the study; grants from Boehringer Ingelheim, Huons, and Hanmi Pharma Korea; and personal fees from Novo Nordisk, Hanmi Pharma Korea, Amgen Korea, and Alvogen Korea outside the submitted work. Dr Overvad is an employee of Novo Nordisk and reported nonfinancial support from OPEN Health Communications during the conduct of the study. Dr Shimomura reported grants from Eli Lilly Japan K.K., Teijin Pharma, Mochida Pharmaceutical, Kowa, Kyowa Kirin, Sumitomo Pharma, Rohto Pharmaceutical, Kobayashi Pharmaceutical, Nissin Foods Holdings, Cancerscan, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Osaka Central Hospital, Hakuhokai Central Hospital, Midori Health Care Center, Kyowakai Medical Corporation, Ono Medical Research Foundation, Suzuken Memorial Foundation, Manpei Suzuki Diabetes Foundation, and Japan Agency for Medical Research and Development; consulting fees from Merck Sharpe & Dohme K.K., Taisho Pharmaceutical, Nippon Boehringer Ingelheim, and Novo Nordisk Pharma; and personal fees from Arcray, Merck Sharpe & Dohme K.K., Astellas Pharma, AstraZeneca K.K., Abbott Japan, Ono Pharmaceutical, Otsuka Pharmaceutical, Kyorin Pharmaceutical, Johnson & Johnson K.K., Kyowa Kirin, Kowa, Sanofi, Sumitomo Pharma, Sanwa Kagaku Kenkyusho, Teijin Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Nipro Corporation, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim, Novartis Pharma K.K., Novo Nordisk Pharma, Mochida Pharmaceutical, Bayer Yakuhin, Pfizer Japan, and Lotte outside the submitted work; participates on the advisory board for AstraZeneca K.K., Novo Nordisk Pharma, Eli Lilly Japan K.K., Amgen, Shionogi & Co., Sumitomo Pharma, and Nissin Foods Holdings; and is an unpaid member of boards for the Japan Society for the Study of Obesity, Japan Endocrine Society, Japan Diabetes Society, Japanese Society for Treatment of Obesity, Japanese Society of Molecular Medicine, Japanese Society of Internal Medicine, Japan Atherosclerosis Society, Japan Society of Metabolism and Clinical Nutrition, and Japanese Society of Anti-Aging Medicine. Dr Thamattoor is an employee of Novo Nordisk and reported nonfinancial support from OPEN Health Communications during the conduct of the study. Dr Kim reported grants from Novo Nordisk during the conduct of the study; grants from Hanmi Pharmaceutical, Alvogen Korea, Huons, Amgen, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and personal fees from Eli Lilly Korea, Novo Nordisk, Hanmi Pharmaceutical, Alvogen Korea, and Chong Kun Dang outside the submitted work. No other disclosures were reported.
PubMed
